Responsiveness to erythropoiesis-stimulating agents and renal survival in patients with chronic kidney disease

Clinical and Experimental Nephrology

Volumn 19, Issue 4, 2015, Pages 598-605

  Kuwahara, Michio ^a   Mandai, Shintaro ^a   Kasagi, Yuri ^a   Kusaka, Keita ^a   Tanaka, Tomomi ^a   Shikuma, Satomi ^a   Akita, Wataru ^a  

^a Shuuwa General Hospital   (Japan)

Author keywords

Renal anemia; Renal death; Responsiveness to ESA

Indexed keywords

ALBUMIN; ANTIANEMIC AGENT; C REACTIVE PROTEIN; CALCIUM; EPOIETIN BETA PEGOL; FERRITIN; HEMOGLOBIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PARATHYROID HORMONE; PHOSPHATE; RECOMBINANT ERYTHROPOIETIN; TRANSFERRIN; UNCLASSIFIED DRUG;

AGED; ANEMIA; ARTICLE; CHRONIC KIDNEY DISEASE; DIABETIC NEPHROPATHY; FEMALE; GLOMERULUS FILTRATION RATE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERPHOSPHATEMIA; MAJOR CLINICAL STUDY; MALE; PROGNOSIS; PROTEIN URINE LEVEL; RISK FACTOR; SURVIVAL; TREATMENT RESPONSE; BLOOD; CHRONIC KIDNEY FAILURE; COMPLICATION; KIDNEY FAILURE, CHRONIC; METABOLISM; MIDDLE AGED; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANEMIA; FEMALE; HEMATINICS; HEMOGLOBINS; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; RENAL INSUFFICIENCY, CHRONIC;

EID: 84940175023     PISSN: 13421751     EISSN: 14377799     Source Type: Journal    
DOI: 10.1007/s10157-014-1023-9     Document Type: Article

References (24)

1. Roth D, Smith RD, Schulman G, Steinman TI, Hatch FE, Rudnick MR, et al. Effects of recombinant human erythropoietin on renal function in chronic renal failure predialysis patients. Am J Kidney Dis. 1994;24:777–84.
2. Kuriyama S, Tomonari H, Yoshida H, Hashimoto T, Kawaguchi Y, Sakai O. Reversal of anemia by erythropoietin therapy retards the progression of chronic renal failure, especially in nondiabetic patients. Nephron. 1997;77:176–85.
3. Roger SD, McMahon LP, Clarkson A, Disney A, Harris D, Hawley C, et al. Effects of early and late intervention with epoetin alpha on left ventricular mass among patients with chronic kidney disease (stage 3 or 4): results of a randomized clinical trial. J Am Soc Nephrol. 2004;15:148–56.
4. Silverberg DS, Wexler D, Blum M, Tchebiner JZ, Sheps D, Keren G, et al. The effect of correction of anaemia in diabetics and non-diabetics with severe resistant congestive heart failure and chronic renal failure by subcutaneous erythropoietin and intravenous iron. Nephrol Dial Transplant. 2003;18:141–6.
5. Go AS, Yang J, Ackerson LM, Lepper K, Robbins S, Massie BM, et al. Hemoglobin level, chronic kidney disease, and the risks of death and hospitalization in adults with chronic heart failure: the anemia in chronic heart failure: outcomes and resource utilization (ANCHOR) study. Circulation. 2006;113:2713–23.
6. Walker AM, Schneider G, Yeaw J, Nordstrom B, Robbins S, Pettitt D. Anemia as a predictor of cardiovascular events in patients with elevated serum creatinine. J Am Soc Nephrol. 2006;17:2293–8.
7. Kuwahara M, Iimori S, Kuyama T, Akita W, Mori Y, Asai T, et al. Effect of anemia on cardiac disorders in pre-dialysis immediately before starting hemodialysis. Clin Exp Nephrol. 2011;15:121–5.
8. Dru¨eke TB, Locatelli F, Clyne N, Eckardt KU, Macdougall IC, Tsakiris D. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med. 2006;355:2071–84.
9. Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006;355:2085–98.
10. Locatelli F, Aljama P, Bárány P, Canaud B, Carrera F, Eckardt KU, et al. Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant. 2004;19(Suppl 2):21–47.
11. KDOQI. KDOQI clinical practice guideline and clinical practice recommendations for anemia in chronic kidney disease update of hemoglobin target. Am J Kidney Dis. 2007;2007(50):471–530.
12. Tsubakihara Y, Nishi S, Akiba T, Hirakata H, Iseki K, Kubota M, et al. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease. Ther Apher Dial. 2010;14:240–75.
13. Zhang Y, Thamer M, Stefanik K, Kaufman J, Cotter DJ. Epoetin requirements predict mortality in hemodialysis patients. Am J Kidney Dis. 2004;44:866–76.
14. Locatelli F, Pisoni RL, Combe C, Bommer J, Andreucci VE, Piera L, et al. Anaemia in haemodialysis patients of five European countries: association with morbidity and mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant. 2004;19:121–32.
15. Robinson BM, Joffe MM, Berns JS, Pisoni RL, Port FK, Feldman HI. Anemia and mortality in hemodialysis patients: accounting for morbidity and treatment variables updated over time. Kidney Int. 2005;68:2323–30.
16. Panichi V, Rosati A, Bigazzi R, Paoletti S, Mantuano E, Beati S, et al. Anaemia and resistance to erythropoiesis-stimulating agents as prognostic factors in haemodialysis patients: results from the RISCAVID study. Nephrol Dial Transplant. 2011;26:2641–8.
17. Rossert J, Gassmann-Mayer C, Frei D, McClellan W. Prevalence and predictors of epoetin hyporesponsiveness in chronic kidney disease patients. Nephrol Dial Transplant. 2007;22:794–800.
18. Solomon SD, Uno H, Lewis EF, Eckardt KU, Lin J, Burdmann EA, et al. Erythropoietic response and outcomes in kidney disease and type 2 diabetes. N Engl J Med. 2010;363:1146–55.
19. de Lurdes Agostinho Cabrita A, Pinho A, Malho A, Morgado E, Faísca M, Carrasqueira H, et al. Risk factors for high erythropoiesis stimulating agent resistance index in pre-dialysis chronic kidney disease patients, stages 4 and 5. Int Urol Nephrol. 2011;43:835–40.
20. Minutolo R, Conte G, Cianciaruso B, Bellizzi V, Camocardi A, De Paola L, et al. Hyporesponsiveness to erythropoiesis-stimulating agents and renal survival in non-dialysis CKD patients. Nephrol Dial Transplant. 2012;27:2880–6.
21. Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53:982–92.
22. Kuwahara M, Hasumi S, Mandai S, Tanaka T, Shikuma S, Akita W, et al. Effects of three kinds of erythropoiesis-stimulating agents on renal anemia in Japanese non-dialysis chronic kidney disease patients. Clin Exp Nephrol. 2013 [Epub ahead of print].
23. Voormolen N, Noordzij M, Grootendorst DC, Beetz I, Sijpkens YW, van Manen JG, et al. High plasma phosphate as a risk factor for decline in renal function and mortality in pre-dialysis patients. Nephrol Dial Transplant. 2007;22:2909–16.
24. Schwarz S, Trivedi BK, Kalantar-Zadeh K, Kovesdy CP. Association of disorders in mineral metabolism with progression of chronic kidney disease. Clin J Am Soc Nephrol. 2006;1:825–31.